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EFFECTS ON PANCREATIC FUNCTION 
Effect of FK 506 on Glucose Metabolism and Insulin Secretion in 
Normal Rats 
W.J. Tze, J. Tai, N. Murase, A. Tzakis, and T.E. Starzl 
FK 506 is a powerful immunosuppressant currently being investigated in clinical transplantation. I In vivo 
administration of this drug resulted in the prolongation of 
skin, liver, kidney, and heart allografts in large and small 
animal models.2•3 The immunosuppressive effect has also 
been shown recently to be effective in the prevention of 
development of diabetes in BB rats.4 In baboons. treat-
ment with FK 506 to prolong kidney allograft survival 
resulted in hyperglycemia in recipient animals.5 In vitro. it 
has been demonstrated that FK 506 does not affect insulin 
secretion from rat and human islets.6•7 Such observations 
suggest that the affect of FK 506 on pancreatic islet cells 
needs closer examination. The present study was under-
taken to assess the in vivo effects of FK 506 treatment on 
glucose metabolism and insulin secretion by the ~ cells in 
normal rats. 
MATERIALS AND METHODS 
Inbred male ACI rats (Harlan Sprague Dawley Inc. Indianapolis. 
Ind) weighing 200 to 300 g were used for all experiments. The 
animals were provided with rat chow and water ad libitum. 
Injectable form of FK S06 (Fujisawa Pharmaceutical Co, Tokyo, 
Japan) was prepared daily in saline and given intramuscularly (1M) 
at I mglkg per day for 14 consecutive days in ACI rats. The 
control animals received saline 1M. 
A standard intravenous (IV) glucose tolerance test (IVGTI I 
g1kg body weight of 2S% dextrose) was performed in overnight 
fasted animals prior to, at I week during, and immediately after 
the 2-week course of FK S06 treatment and following discontin-
uation of FK S06 injections at 2, 4, and 8 weeks. Blood was taken 
at 0; I, 3, S, 10, IS, 30, 4S, 60, 90, and 120 minutes for blood 
glucose (Beckman Glucose Analyzer, Beckman Instruments) and 
insulin (Pharmacia RIA Kit, Montreal) determination. In addition, 
an oral glucose tolerance test (OGTI, 2 gIkg body weight of 20% 
dextrose) was also performed I day after the IVGTI in some 
animals. Blood was taken at 0, IS, 30, 60, 90, and 120 minutes for 
glucose determination. Rat insulin standard was a generous gift 
from E. Lilly Co, Indianapolis, Ind. 
Data were analyzed statistically by Student's t test with the 
level of significance set at P < .OS. 
RESULTS 
Fig 1 shows that the glucose tolerance curve in normal ACI 
rats became abnormal after 1 week of FK 506 injections, 
and worsened after the second week of injections. 
Fig 2 shows that there was improvement in glucose 
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Fig 1. Effect of the duration of FK 506 treatment (1 mg/kg per day 
1M) on glucose tolerance curves following IVGTT (1 g/kg body 
weight) in ovemight-fasted ACI rats (l\-l\ before treatment, n = 
14, mean :t: SEM; V-V 1 week, n = 8; and 0-0 2 weeks, n = 
14 of FK 506). 
tolerance by 2 weeks after the stoppage of FK 506 injec-
tions and a near normal curve was obtained after 1 montr 
Four groups of rats were tested showing insignifica~I 
variation in results among the groups. The overall resui[ 
would indicate that it required approximately I month for 
normalization of the glucose tolerance curve following 
discontinuation of the medication. 
Fig 3 shows the oorr glucose curves in ACI rats 
treated with 1 mglkg per day for 2 weeks. The glucose 
tolerance curve was abnormal following FK 506 treatment 
in these animals, and it worsened after 2 weeks of discon-
tinuation of medication. However. a normal glucose curve 
returned 4 weeks after stoppage of FK 506 treatment. 
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EFFECT OF FK 506 ON GLUCOSE METABOLISM 
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Fig 2. Effect of FK 506 treatment (1 mg/kg per day 1M for 2 
weeks) on glucose tolerance curves following IVGTT (1 g/kg BW) 
in overnight-fasted ACI rats (0-0 before treatment, n = 35, 
mean::!: SEM; t:"-t:,, 2 weeks of FK 506, n = 33; V-V 2 weeks, 
n = 14; and <J-<J 4 weeks, n == 16, after discontinuation of FK 
506). 
Fig 4 summarizes the effect of 2 weeks of FK 506 
treatment at 1 mg/kg per day on the insulin profiles in ACI 
rats following IVOn. Before FK 506 treatment, two 
insulin peaks were observed. The initial peak at 1 minute 
was significantly higher than the second peak at 15 minutes 
and then the insulin levels gradually declined to above 
basal level at 2 hours. After the 2-week course of FK 506 
treatment, the first insulin peak in response to IVOn was 
similar to the controls, while the second peak disappeared. 
Complete normalization of insulin profile was observed 
when the animals were retested 8 weeks after discontinu-
ation of FK 506 treatment. 
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Fig 3. Effect of FK 506 treatment (1 mg/kg per day 1M for 2 
weeks) on glucose tolerance curves following OGTT (2 g/kg body 
weight) in overnight-fasted ACI rats (0-0 normal controls, n = 
24, mean ::!: SEM; t:"-t:,, 2 weeks of FK 506, n == 8; V-V 2 
weeks; and <J-<J 4 weeks after discontinuation of FK 506). 
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Fig 4. Effect of FK 506 treatment (1 mg/kg per day for 2 weeks) 
on insulin profiles following IVGTT (1 g/kg body weight) in over-
night-fasted ACI rats (0-0 before treatment, n == 10, mean ::!: 
SEM; t:"-t:,, 2 weeks of FK 506, n == 9; V-V 4 weeks; n == 13; 
and <1-<18 weeks, n == 8, after discontinuation of FK 506). 
DISCUSSION 
FK 506 is a powerful immunosuppressant which has been 
used in a clinical trial in organ transplantation, and also 
found to be effective in the prevention of the development 
of diabetes in BB rats. 1.4 The biological activities of this 
drug are similar to CyA, and CyA at high doses is known 
to affect the glucose metabolism of recipients. 8 It was 
previously reported that rats on oral form of FK 506 
between I and 4 mg/kg per day for 34 days tend to have 
high blood glucose levels but no detailed study was con-
ducted.9 This observed side effect would be more impor-
tant when FK 506 is used as immunosuppressant in the 
treatment of newly diagnosed type I diabetics and as a 
antirejection agent in islet cell transplantation. We pres-
ently observed that FK 506 treatment at I mg/kg per day 
for 2 weeks did not significantly affect the basal glucose 
and insulin levels in the treated ACI rats. However, this 
treatment with FK 506 altered their glucose tolerance. The 
derangement of glucose metabolism in the rats treated with 
FK 506 was not permanent. Glucose profiles following 
IVOn were nearly normalized by about 4 weeks after 
stoppage of the agent, and return to normality was ob-
served when the animals were retested by 8 weeks. The 
normalization of BG profile preceded that of insulin profile 
by 2 to 4 weeks. The mechanism underlying the effect of 
FK 506 on glucose metabolism remains to be determined. 
The insulin profiles following IVGn in the treated rats 
would support the view that the effect was most likely due 
to decreased insulin release from {3 cells. 
This study confirmed that FK 506, at high doses, can 
affect glucose metabolism in rats in vivo. This would 
support the in vitro observation that FK 506 affected islet 
insulin synthesis and response to glucose challenge in vitro 
at a high concentration.6 The FK 506 treatment regimen is 
currently being used in our laboratory for islet allotrans-
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plantation studies. It was found to be effective in the 
prolongation of allografts across a major histocompatibility 
bamer. 
The present duta showed that FK 506 given 1M at 1 
mglkg per day for up to 2 weeks can cause temporary 
deterioration of the glucose metabolism in the recipients. 
This effect on carbohydrate metabolism is reversible and 
will not limit the value of FK 506 in transplantation. 
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